

Date: April 03, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Media Release – “Senores Pharmaceuticals, Inc. announces Strategic Joint Venture in the United States, positioning the group for U.S. Federal and Defense Sector Supplies”

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of Media Release being issued by the Company on the captioned subject.

The same is also being uploaded on the website of the Company at www.senorespharma.com.

This is for information and records.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As mentioned above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

MEDIA RELEASE

SENORES PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC JOINT VENTURE IN THE UNITED STATES, POSITIONING THE GROUP FOR U.S. FEDERAL AND DEFENSE SECTOR SUPPLIES

Atlanta, USA / Ahmedabad, India, April 03, 2026 – Senores Pharmaceuticals, Inc. (“**SPI**”), USA, a wholly owned subsidiary of Senores Pharmaceuticals Limited (the “**Company**”), announced that it has successfully entered into a strategic partnership by executing a formal Operating Agreement on April 2, 2026. This Agreement marks a decisive milestone in Senores’ international expansion and its strategic entry into the U.S. government procurement market. The partnership has been formalized through the formation of a Joint Venture (“**JV**”) entity, namely Amerisyn, LLC (“**Amerisyn**”).

Strategic Gateway to U.S. Federal Contracts

The partnership represents a structural leap for Senores’ US operations. Through the establishment of this JV framework, Senores is now strategically positioned to facilitate the supply of its high-quality product portfolio to the U.S. Federal Government, veterans affairs and military supply contracts and leverage specialized credentials to participate in long-term national contracts and government supply tenders.

Management Commentary

"Amerisyn is a major milestone for Senores. This will enable Senores to utilise its manufacturing and product expertise for supply to the U.S. government sector and unlock a high-entry-barrier market. We expect this partnership to be a significant driver of growth and a substantial contributor to our international business volumes moving forward." stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited.

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited (together with its subsidiaries “**Senores**”) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The Companies’ current portfolio includes 46 ANDAs and 137 strengths along with a pipeline of 22 ANDAs and 52 strengths. In the CMO/CDMO vertical 16 ANDAs and 34 products permitted for distribution in the USA along with a pipeline of 16 ANDAs and 35 strengths. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 450 product registrations and 858 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“**API**”).

Senores has 3 manufacturing facilities for formulations – one in Atlanta, US which is USFDA

approved and DEA, TAA & BAA compliant for controlled substances and government supplies, second is in Baroda, which is a USFDA, Health Canada and UKMHRA approved site & third is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbor Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

For more information, please contact:

Company: Senores Pharmaceuticals Limited
CIN: L24290GJ2017PLC100263

Mr. Deval Shah
Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

Investor Relations: Strategic Growth Advisors
CIN: U74140MH2010PTC204285

Mr. Sagar Shroff / Mr. Tanay Shah
M: +91 98205 19303 / +91 98333 91899
E-mail: sagar.shroff@sgapl.net / tanay.shah@sgapl.net
For updates and specific queries, please visit www.sgapl.net
